Stock Performance Overview
The stock has been on a downward trajectory, registering losses for four consecutive days and falling by 7.56% during this period. On the day it hit the all-time low, the share price dropped by 1.37%, underperforming the Sensex, which gained 1.15%. Over the past week, the stock declined by 5.66%, compared to a 3.34% fall in the Sensex. The one-month and three-month returns were down by 13.43% and 16.45% respectively, both lagging behind the Sensex’s declines of 10.57% and 13.91%. The year-to-date performance also reflected a negative trend with a 15.99% fall against the Sensex’s 13.72% drop.
Longer-term figures reveal a more pronounced underperformance. Over the last year, Mukka Proteins Ltd’s stock has plummeted by 40.50%, starkly contrasting with the Sensex’s modest 5.71% decline. The stock has shown no growth over the past three, five, and ten years, while the Sensex has delivered returns of 27.82%, 49.51%, and 190.21% respectively over the same periods.
Technical Indicators and Market Positioning
Technically, the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained bearish trend. The overall technical trend is mildly bearish, having shifted from a bearish stance on 1 February 2026 when the price was ₹23.45. Key resistance levels are identified at ₹22.04 (20-day moving average), ₹23.74 (100-day moving average), and ₹25.97 (200-day moving average), while immediate support stands at ₹20.20, the 52-week low.
Technical indicators present a mixed picture: the MACD and Bollinger Bands suggest bearish momentum, while the RSI shows no clear signal on a weekly basis but a bullish indication monthly. The KST indicator is mildly bullish, yet the Dow Theory remains bearish on the weekly timeframe. Delivery volumes have increased notably, with a 49.86% rise on the day of the price drop compared to the 5-day average, indicating heightened trading activity amid the decline.
Fundamental and Financial Analysis
Mukka Proteins Ltd operates within the FMCG sector and is classified as a micro-cap company. Its MarketsMOJO score stands at 37.0, with a current grade of ‘Sell’, upgraded from a ‘Strong Sell’ on 14 November 2025. The company’s financial fundamentals have shown signs of strain over the medium to long term.
Over the past five years, the company’s operating profits have contracted at a compound annual growth rate (CAGR) of -4.98%. The return on capital employed (ROCE) averages 9.16%, indicating modest profitability relative to the capital invested. The company’s debt servicing capacity is limited, with a high Debt to EBITDA ratio of 5.26 times, reflecting significant leverage and potential financial risk.
Institutional investor participation has diminished, with holdings dropping by 1.5% in the previous quarter to a collective stake of just 1.86%. This reduced institutional presence may reflect cautious sentiment given the company’s financial profile and recent performance.
Valuation and Quality Metrics
At the current price of approximately ₹20.17, Mukka Proteins Ltd trades at a price-to-earnings (P/E) ratio of 14 times and a price-to-book value (P/BV) of 1.38 times. The enterprise value to EBITDA ratio stands at 10.66 times, while the EV to capital employed is 1.17 times, suggesting the stock is valued at a discount relative to its peers’ historical averages.
The company’s quality assessment remains below average, with weak growth, capital structure, and management risk ratings. Key financial ratios include a 5-year sales growth of -3.07%, an average EBIT to interest coverage of 2.87 times, and a net debt to equity ratio of 1.25, underscoring elevated leverage. The average return on equity (ROE) is 10.63%, which is modest within the FMCG sector context.
Recent Quarterly Financials
Despite the broader downtrend, the company reported positive quarterly results in December 2025, breaking a streak of seven consecutive quarters of negative outcomes. Net sales for the quarter reached ₹653.50 crores, representing a 137.6% increase compared to the average of the previous four quarters. Profit after tax (PAT) rose by 101.1% to ₹23.75 crores, while PBDIT reached a quarterly high of ₹45.44 crores. However, interest expenses also increased by 28.18% over the last six months to ₹27.38 crores, reflecting the cost of servicing elevated debt levels.
Comparative Sector and Market Context
Within the FMCG sector, Mukka Proteins Ltd’s stock has underperformed its peers and broader market indices consistently over multiple time horizons. The BSE500 index has outpaced the stock’s returns over the last three months, one year, and three years, highlighting the relative weakness of the company’s equity performance.
While the company’s valuation metrics suggest an attractive entry point on a relative basis, the underlying financial and operational indicators point to ongoing challenges that have contributed to the stock’s decline to historic lows.
Summary
Mukka Proteins Ltd’s stock reaching an all-time low of ₹20 on 24 March 2026 reflects a culmination of sustained price depreciation amid weak financial performance, high leverage, and diminished institutional interest. The stock’s technical and fundamental indicators collectively illustrate a company facing considerable headwinds within the FMCG sector, with valuation metrics signalling a discount relative to historical norms and peers. The recent quarterly improvement in sales and profits offers a nuanced view but has not yet translated into a reversal of the broader downtrend in the share price.
